Several biological therapies, mainly targeting type 2 inflammation, have been shown to be effective in reducing asthma exacerbation, be corticosteroid-sparing, improving lung function and/or improving quality of life in patients with severe asthma. Evidence is accumulating that also in upper airway disease, such as chronic rhinosinusitis with nasal polyps (CRSwNP), these therapies are effective and can reduce nasal polyp size, improve the patients’ Qol and positively impact lower airway outcome parameters.

Panellists: Prof. Peter Hellings, Prof. Claus Bachert, Prof. Wytske Fokkens, Prof. Guy Joos, Prof. Renaud Louis, Prof. Charles Pilette, Prof. Glenis Scadding, Dr. David Price and patient representatives.

Stay in touch for further news from EUFOREA!

🌐 Visit our website: [ Ссылка ]

➡️ Follow us on Facebook: [ Ссылка ]
➡️ Follow us on LinkedIn: [ Ссылка ]
➡️ Follow us on Twitter: [ Ссылка ]
​
📌 EUFOREA is an international non-profit organization forming an alliance of all stakeholders dedicated to reduce the prevalence and burden of allergies and airway diseases through the implementation of optimal patient care through education, research and advocacy.
--------------------------------------------------------------------------------------------------------------------------
Subscribe to our YouTube Channel for our latest videos within Allergies and Airway Diseases
[ Ссылка ]
--------------------------------------------------------------------------------------------------------------------------
Get in touch with EUFOREA team for any questions
[ Ссылка ]

#EUFOREA

свернуть